跳至主要内容
临床试验/NCT06637813
NCT06637813尚未招募不适用

Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudine

Fondazione Policlinico Universitario Agostino Gemelli IRCCS0 个研究点目标入组 1,220 人开始时间: 2024年10月30日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
1,220
主要终点
Establishment of a database

研究概览

简要总结

The introduction of combination antiretroviral therapy (cART) has completely revolutionized the management of HIV-positive patients, drastically reducing HIV-associated mortality and morbidity. In fact, the course of HIV infection has transformed into a chronic disease. The availability of different classes of antiretroviral drugs, such as nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs, NNRTIs), protease inhibitors (PIs), integrase inhibitors (INSTIs) and viral entry inhibitors (IEs) that act in different phases of the HIV life cycle, together with careful patient management, has allowed us to obtain long-lasting therapeutic efficacy in the vast majority of Italian patients, making this infection a chronic disease.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • signed informed consent
  • patients treated with triple therapy who simplify to 3TC+DTG
  • patients treatment-naive who start a dual therapy with 3TC+DTG from clinical practice

排除标准

  • lack of willingness to provide informed consent

结局指标

主要结局

Establishment of a database

时间窗: 10 years

Systematic and continuous collection of data related to clinical, laboratory and treatment characteristics of patients who simplify from triple standard ART or who continue dual therapy with 3TC+DTG, or treatment-naive patients who start the dual regimen with 3TC+DTG. The data will be useful for the evaluation of diagnostic and multiparametric algorithms.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验